- $261.42bn
- $288.76bn
- $58.74bn
Brief: AstraZeneca Says Enhertu Demonstrates 14.3 Month Median Progression-Free Survival In Destiny-Lung04 Phase III Trial
Brief: AstraZeneca Says Tagrisso® (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial
AstraZeneca's breast cancer pill fails in late-stage trial (updated)
Brief: AstraZeneca Says SERENA-4 Phase III Trial Of Etcamah With Palbociclib Does Not Meet Primary Endpoint
Astrazeneca's breast cancer drug fails late-stage trial
Focus: Novartis investors turn spotlight on M&A after trial setbacks
Europe Research Roundup: AstraZeneca, GSK, Kingspan Group
Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial (updated)
Health Rounds: AstraZeneca drug reduces lung disease flare-ups in late-stage trials
Corrected: UPDATE 1-Amgen-AstraZeneca drug combo helps lung cancer patients live longer in late-stage study
Corrected: Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial
Imfinzi+Imdelltra improved OS in small cell lung
Brief: AstraZeneca says Tozorakimab significantly and meaningfully reduces COPD exacerbations in Phase III trials
Press Digest: British Business - September 8
Brief: Astrazeneca Says Etcamah Approved In US For HR+ Breast Cancer
Etcamah approved in the US for HR+ breast cancer
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Admission of Further Securities to Trading
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements